Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells.

Marrazzo A, Fiorito J, Zappalà L, Prezzavento O, Ronsisvalle S, Pasquinucci L, Scoto GM, Bernardini R, Ronsisvalle G.

Eur J Med Chem. 2011 Jan;46(1):433-8. doi: 10.1016/j.ejmech.2010.10.012. Epub 2010 Oct 15.

PMID:
21055848
2.

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.

Clin Cancer Res. 2006 Sep 1;12(17):5199-206.

3.

MRJF4, a novel histone deacetylase inhibitor, induces p21 mediated autophagy in PC3 prostate cancer cells.

Di Giacomo V, Di Valerio V, Rapino M, Bosco D, Cacciatore I, Ciulla M, Marrazzo A, Fiorito J, Di Stefano A, Cataldi A.

Cell Mol Biol (Noisy-le-grand). 2015 Jun 8;61(3):17-23.

PMID:
26068914
4.
5.

Synthesis and evaluation of haloperidol metabolite II prodrugs as anticancer agents.

Dichiara M, Amata E, Rescifina A, Prezzavento O, Floresta G, Parenti C, Pittalà V, Marrazzo A.

Future Med Chem. 2017 Oct;9(15):1749-1764. doi: 10.4155/fmc-2017-0064. Epub 2017 Sep 4. Review.

PMID:
28869398
6.

Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells.

Sozio P, Fiorito J, Di Giacomo V, Di Stefano A, Marinelli L, Cacciatore I, Cataldi A, Pacella S, Turkez H, Parenti C, Rescifina A, Marrazzo A.

Eur J Med Chem. 2015 Jan 27;90:1-9. doi: 10.1016/j.ejmech.2014.11.012. Epub 2014 Nov 6.

PMID:
25461306
7.
8.
9.
10.
11.

Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation.

Rybczynska AA, Dierckx RA, Ishiwata K, Elsinga PH, van Waarde A.

J Nucl Med. 2008 Dec;49(12):2049-56. doi: 10.2967/jnumed.108.053876. Epub 2008 Nov 7.

12.

Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors.

John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD.

Cancer Res. 1999 Sep 15;59(18):4578-83.

13.

Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.

Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH.

Int J Oncol. 2004 Jan;24(1):25-31.

PMID:
14654937
14.

[Functional characterization of a sigma receptor and its gene expression by haloperidol].

Nakata Y, Inoue A, Sugita S.

Nihon Yakurigaku Zasshi. 1999 Jul;114(1):61-8. Review. Japanese.

PMID:
10562966
15.

Signalling via rat dopamine D2-receptors expressed in mouse fibroblasts is not influenced by compounds binding to the sigma sites of these cells.

Sommermeyer H, Dompert WU, Glaser T.

Cell Signal. 1993 Nov;5(6):747-52. Erratum in: Cell Signal 1994 Feb;6(2):245.

PMID:
8130078
16.

Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.

Frønsdal K, Saatcioglu F.

Prostate. 2005 Feb 15;62(3):299-306.

PMID:
15389787
17.

Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.

Entrena JM, Cobos EJ, Nieto FR, Cendán CM, Baeyens JM, Del Pozo E.

Psychopharmacology (Berl). 2009 Jul;205(1):21-33. doi: 10.1007/s00213-009-1513-8. Epub 2009 Mar 27.

18.
19.

1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: Mixed σ and human Δ(8)-Δ(7) sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity.

Abate C, Niso M, Contino M, Colabufo NA, Ferorelli S, Perrone R, Berardi F.

ChemMedChem. 2011 Jan 3;6(1):73-80. doi: 10.1002/cmdc.201000371.

PMID:
21069657
20.

Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.

Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S.

Cancer Res. 2004 Jul 15;64(14):4875-86.

Supplemental Content

Support Center